secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2026-06-23T20:19:56+00:00
Accession:  0001193125-26-279483
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Olema shareholders elect directors, approve executive compensation, ratify auditor at 2026 annual meeting
--------------------------------------------------------------------------------

- Four Class III directors elected: Bohen (67.5M for), Garland (66.2M), Larson (50.4M), Rappaport (67.3M).
- Advisory vote on executive compensation approved: 68.0M for, 654K against, 15.9K abstain.
- Ernst & Young ratified as independent auditor for FY2026: 75.8M for, 272K against, 52.5K abstain.
- Broker non-votes of 7.5M on director and compensation proposals; none on auditor ratification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526279483/0001193125-26-279483-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000119312526279483/olma-20260617.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-279483

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer